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Abstract: Active targeting by means of drug encapsulated nanoparticles decorated with 
 targeting bioactive moieties represents the next frontier in drug delivery; it reduces drug side 
effects and increases the therapeutic index. Peptides, based on their chemical and biological 
properties, could have a prevalent role to direct drug encapsulated nanoparticles, such as lipo-
somes, micelles, or hard nanoparticles, toward the tumor tissues. A considerable number of 
molecular targets for peptides are either exclusively expressed or overexpressed on both cancer 
vasculature and cancer cells. They can be classified into three wide categories: integrins; growth 
factor receptors (GFRs); and G-protein coupled receptors (GPCRs). Therapeutic agents based 
on nanovectors decorated with peptides targeting membrane receptors belonging to the GPCR 
family  overexpressed by cancer cells are reviewed in this article. The most studied targeting 
membrane receptors are considered: somatostatin receptors; cholecystokinin receptors;  receptors 
associated with the Bombesin like peptides family; luteinizing hormone-releasing hormone 
receptors; and neurotensin receptors. Nanovectors of different sizes and shapes (micelles, lipo-
somes, or hard nanoparticles) loaded with doxorubicin or other cytotoxic drugs and externally 
functionalized with natural or synthetic peptides are able to target the overexpressed receptors 
and are described based on their formulation and in vitro and in vivo behaviors.
Keywords: receptors binding peptides, drug delivery, nanoparticles, supramolecular aggregates, 
active targeting
Introduction
Oral and intravenous administration of drugs is generally utilized for systemic 
treatment. Such methods deliver fixed concentrations of drugs to all organs and tis-
sues in the body. In many cases, only a small amount of the administered molecules 
reaches the target organ. A challenge for drug therapy research is to selectively target 
drugs to diseased organs and tissues. This would allow more efficient use of drugs 
by achieving higher concentrations in target organs and lowering concentrations in 
remaining tissues, with a consequent reduction of side effects. This goal has pushed 
scientists to develop carriers capable of driving and localizing drugs.1
The pharmacokinetic and pharmacodynamic properties of the active drug thus 
become dependent on the pharmacokinetics of its carrier. A drug may be bound to 
the carrier covalently, through Van der Waals interactions, or it may be enclosed in 
supramolecular aggregates. For the latter option, the carrier also serves as a means for 
controlled drug release. Targeted drug delivery is appealing for application in a variety 
of diseases, such as cardiovascular diseases2 and diabetes;3 however, the area of main 
interest for the application of these methods is in oncology, where concentration of the 
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drug in tumor cells is a crucial issue. Most chemotherapeutic 
drugs target some aspect of cell proliferation to exert their 
therapeutic effect. Therefore, most side effects are linked to 
the activity of these drugs on normal tissues with rapid cell 
proliferation such as the bone marrow.4 Different strategies 
are being investigated in order to improve targeting of drugs 
to cancer cells. In passive targeting, increased delivery of the 
drug to target cells is achieved by taking advantage of the 
intrinsic properties of the tumor vasculature which permits 
an increase in the non-specific trapping of drugs, whereas 
active targeting is based on the use of tumor targeting bioac-
tive compounds to drive drug accumulation.
Passive targeting
Matsumura and Maeda proposed that passive targeting may 
be exploited through a mechanism known as the Enhanced 
Permeability and Retention (EPR) effect.5 The EPR effect is 
based on enhanced vascular permeability in the tumor due 
to blood vessel overgrowth. It facilitates transport of mac-
romolecules or nanoparticles into tumor tissues, allowing 
accumulation of drug-based nanomaterials on tumor cells 
and their retention for an extended period of time (days to 
weeks). In passive targeting, macromolecules of a certain size 
(10–500 nm) remain in circulation for an extended period 
of time and are taken up into cells by vesicular uptake pro-
cesses (endocytosis). On the contrary, intravenously injected 
particles smaller than 5 nm are removed from the blood by 
rapid renal clearance through the kidneys, while very large 
microsized particles are filtered mechanically by the sinu-
soids and cleared by the reticuloendothelial system (RES) 
of the liver and spleen. Moreover, surface hydrophobicity 
and charged systems are more prone to opsonization and 
are consequently taken up by the RES, even when the size 
is within the specified limits.6 In contrast, neutral particles 
have a low opsonization.
The drug carriers that are most frequently utilized for this 
purpose are micelles and liposomes. Micelles (diameter range 
5–50 nm) are composed of surfactant molecules dispersed 
in a liquid colloid. For drug delivery applications, polymeric 
micelles can be obtained by self-assembling amphiphilic 
copolymers in aqueous solution. These aggregates typically 
display a spherical structure, where the hydrophilic head of 
the composing monomers is in contact with the surrounding 
aqueous solution; hydrophobic tail regions are sequestered 
in the inner core. The densely packed core consists of hydro-
phobic blocks (less than 2,000 g/mol) while the shell consists 
of poly(ethylene oxide) (PEO). An adequately high number 
of PEO chains can prevent protein adsorption and cellular 
 adhesion, steps which precede mononuclear phagocyte 
system (MPS) uptake in the RES extending blood-circulation 
time. Moreover, this polymer is inexpensive, has a low 
toxicity, and has been approved for internal applications by 
regulatory agencies.7 Poorly hydrophilic drugs can also be 
loaded in the micelle core.8
Polymeric micelles synthesized as biocompatible and 
biodegradable drug carriers include aggregates obtained 
with: 1) PEO-b-poly(P-benzyl-L-aspartate) (PEO-PBLA);9 
2) PEO-b-poly(L-lactic acid) (PEO-PLA);10 and 3) PEO-
lipid conjugates. Micelles of PEO-PBLA, PEO-PLA, and 
PEO lipid conjugates allow better dispersion of hydro-
phobic anticancer drugs such as taxol and etoposide.11 
It is possible to tailor the cores of polymeric micelles in 
order to solubilize drugs of varying polarity, for example 
polymeric micelles having a poly(L-amino acid) core can 
take up and protect water-insoluble drugs.12,13 Controlled 
levels of doxorubicin (DOX), a hydrophilic anthracycline 
analog and one of the most frequently prescribed antineo-
plastic agents for cancer chemotherapy, have been suc-
cessfully loaded into micelles of PEO-h-poly(aspartate)14 
or PEO-PBLA.15
Some other hydrophilic polymers may be used as 
 hydrophilic blocks.16 Among possible alternatives to 
PEO, poly(N-vinyl-2-pyrrolidone) (PVP), which is highly 
biocompatible17 and could be employed in diblock poly-
mer micelles,18 polyvinyl alcohol (PVA), and poly(vinyl 
 alcohol-co vinyl oleate) co-polymer, which was used to pre-
pare micelles enhancing transcutaneous permeation of retinyl 
palmitate, have been proposed.19 PVA substituted with oleic 
acid has also been used for carrying lipophilic drugs.20
There are several examples of drug-loaded polymeric 
micelles for anticancer therapy being evaluated in preclini-
cal studies with the aim of improving therapeutic efficacy. 
Micelle formulations being tested in clinical trials are 
 summarized in Table 1.
Liposomes (diameter range 50–500 nm) are structurally 
different from micelles for the presence of a bilayer mem-
brane. Liposomes encapsulate a region of aqueous solution 
inside the membrane; hydrophilic solutes, that are not able to 
readily pass through the lipids, remain dissolved in the aque-
ous inner core. The formation is often driven by phosphati-
dylcholine enriched phospholipids. Since their discovery 
and introduction in the mid-1960s by Bangham and Horne,21 
liposomes have been proposed as a shuttle to deliver a wide 
range of encapsulated hydrophilic drugs. Moreover, hydro-
phobic chemicals can also be loaded into the membrane, 
and in this way liposomes can carry both  hydrophobic and 
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Table 1 Micellar formulations being currently tested in clinical trials
Polymeric micelle Block copolymer Drug Indication Clinical phase
NK012 PeG-PGlu(SN-38) SN-38 Breast cancer II
NK105 PeG-P(aspartate) Paclitaxel Advanced stomach cancer II
SP1049C Pluronic L61 and F127 Doxorubicin Adenocarcinoma of esophagus,  
gastroesophageal junction and stomach
III
NC-6004 PeG-PGlu(cisplatin) Cisplatin Solid tumors I/II
Genexol-PM PeG-P(D,L-lactide) Paclitaxel Breast cancer Iv
Genexol-PM PeG-P(D,L-lactide) Paclitaxel Pancreatic cancer II
Genexol-PM PeG-P(D,L-lactide) Paclitaxel Non-small-cell lung cancer in  
combination with carboplatin
II
Genexol-PM PeG-P(D,L-lactide) Paclitaxel Pancreatic cancer in combination with 
gemcitabine
I/II
Genexol-PM PeG-P(D,L-lactide) Paclitaxel Ovarian cancer in combination with  
carboplatin
I/II
Abbreviations: PeG, polyethylene glycol; SN38, 7-ethyl-10-hydroxy-camptothecin.
hydrophilic drugs. In the last 20 years, a major  development 
has been the formulation of  polyethylene glycol (PEG)
ylated liposomes (PEG-liposomes), known as stealth lipo-
somes, with a prolonged circulation time in the blood.22 
PEG-liposomes contain polyethylene glycol derivatives of 
phosphatidylethanolamine (PEG-lipid). The major differ-
ence compared to PEO is the molecular weight of the ethoxyl 
chain that is below 20,000 Daltons.  Nowadays, eleven drugs 
with liposomal delivery systems have been approved by the 
US Food and Drug Administration (FDA) and six additional 
liposomal drugs are in advanced phase clinical trials. Two of 
these liposomal systems are employed in cancer therapy. The 
first stealth liposome was approved in 1995 by the US FDA 
and is still the only formulation to be approved (in the United 
States as DOXIL® [Alza Corporation, Vacaville, CA, USA] 
and in Europe as Caelyx® [Janssen Pharmaceutica, Beerse, 
Belgium]), for the treatment of Kaposi’s sarcoma23 and recur-
rent ovarian cancer.24 DOXIL liposomes are  approximately 
100 nm in diameter with the following lipid composi-
tion (expressed as percentage mole ratio):  hydrogenated 
 soybean phosphatidylcholine (56.2%),  cholesterol (38.3%), 
polyethylene-glycol (molecular weight [MW] 1,900) 
derivatized distearoyl- phosphatidylethanolamine (5.3%), 
and α-tocopherol (0.2%). Loading of doxorubicin 
(0.125 drug/lipid weight ratio) is based on the ammonium 
sulfate gradient method.
The combined use of drugs acting on different targets 
within cancer cells is widely utilized in oncology to improve 
efficacy, overcome undesirable toxicity, reduce the admin-
istered amounts of each agent, and reach multiple targets – 
thereby increasing the therapeutic index of the native drugs.24 
Supramolecular aggregates are theoretically capable of 
loading more than one drug at a time, which would allow 
for the simultaneous delivery of multiple drugs.25 Such an 
approach may be of additional value for clinical application 
of these delivery systems. Several examples of micelles and 
liposomes acting as co-delivery transporters are reported in 
the literature.26,27
Aside from the aforementioned aggregates generally 
belonging to the soft matter category, hard matter carriers, 
such as metal nanoparticles and ceramic nanoparticles, 
have been developed in recent years for their applications 
in diagnostics and therapeutics.28 One carefully studied 
metal nanoparticle is iron oxide, which can be used for 
such purposes after being coated with dextran, surfactants, 
phospholipids, or other compounds that increase its stability. 
Also, aminosilane-coated iron oxide nanoparticles have been 
utilized in thermotherapy to treat brain tumors.29
Magnetic nanoparticles (MNPs) of iron oxide possess 
unique magnetic properties and have the ability to function 
at the cellular and molecular level of biological interactions. 
Such nanoparticles are attractive for applications in thermo-
therapy, as contrast agents for magnetic resonance imaging 
(MRI) and as carriers for drug delivery.30 Other early nano-
technology approaches toward the chance of overcoming 
multidrug resistance (MDR) in cancer include covalent 
attachment of drug to polymers and solid-core nanopar-
ticles to prevent drug efflux.31 Recently, DOX conjugated 
 superparamagnetic iron oxide nanoparticles (SPION; 
NP-DOX) were developed and examined for susceptibil-
ity to MDR mediated drug efflux, a common mechanism 
of resistance to DOX.32 Metal nanoparticles utilizing gold 
have good optical and chemical properties and are being 
investigated for use in infrared phototherapy applications. 
Ceramic nanoparticles such as silica, titania, and alumina 
are generally bioinert and have porous structures. These 
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 nanoparticles have also been proposed as drug delivery 
vehicles for cancer therapy.33
Nanoparticles have several features that make them 
appealing for these applications: a large surface area that 
allows them to trap an elevated number of active drug mole-
cules; their structural versatility that allows them to obtain 
objects of varying sizes and pharmacokinetic properties in 
order to optimize drug delivery; and the possibility of cou-
pling with other molecules, such as pharmacokinetic modi-
fiers (PEG) or labels that can be used for tracking (magnetic, 
radioactive, or fluorescent).
Active targeting
The currently approved nanoparticle systems have, in some 
cases, improved the therapeutic index of approved drugs by 
reducing drug toxicity or enhancing drug efficacy. However, 
there are data indicating that PEGylated liposomes loaded 
with doxorubicin34 do not significantly improve therapeutic 
efficacy compared to the native carrier free drug. An explana-
tion for these results may be that PEGylated liposomes only 
increase drug concentration in the tumor vasculature, but 
there is no significant change in the intracellular drug level, 
which is crucial for efficacy.
Therefore, active targeting is being actively pursued in 
order to target delivery. This approach is based on utilizing 
nanoparticles that have been externally modified with bio-
active molecules capable of selectively recognizing targets 
present in cancer.
Different systems are used to provide targeting capa-
bilities and these include monoclonal antibodies, receptor-
specific peptides or proteins, nucleic acids (deoxyribonucleic 
acids/ribonucleic acids [DNA/RNA] aptamers), small 
mole cules, and even vitamins or carbohydrates. Monoclonal 
antibodies or antibody fragments that can be selected with a 
high degree of specificity for the target tissue, with elevated 
binding affinities, are therefore particularly suitable for this 
task. Antibodies are being used to deliver radioisotopes,35 
toxins,36 cytokines,37 and other drugs. In certain settings 
the targeting antibody also displays therapeutic properties38 
 giving the added advantage of targeting the cancer cell by 
two distinct mechanisms. Despite the recent progress in 
antibody engineering, antibody development is still fairly 
expensive and use of such biomolecules as drugs presents 
stability and storage problems when designing formula-
tions for clinical use. Another issue that may arise with 
non-humanized antibodies is immunogenicity, which may 
limit repeat administrations due to the risk of significant 
side effects.
On the other hand, several non-antibody ligands can be 
coupled to larger drug vectors for this same purpose. This 
class of compounds may display less selective interaction 
with potential targets. Ligands such as folate and transferrin, 
which target growth-factor receptors,39,40 have targets that are 
expressed not only in cancer cells but also in normal tissues. 
There are also physiological concentrations of native ligands 
that may compete for the target.
Peptide targeting
Natural and synthetic peptides are a class of small ligands 
that have great potential for such applications. They offer the 
advantage of providing infinite sequence/structure possibili-
ties that can potentially be designed to bind to any cancer 
related target. Furthermore, such an approach is expected 
to yield fewer problems related to immunogenicity. Among 
potential targets, there are several cell surface receptor 
 systems that have small peptides as ligands that have been 
shown to be highly expressed in a variety of neoplastic and 
non-neoplastic cells.41  Furthermore, receptor-targeting pep-
tides have shown a high level of internalization within tumor 
cells via receptor-mediated endocytosis. Such a feature of 
these systems may be of value in facilitating intracellular 
delivery of the intended payload. The drawbacks related to the 
use of these compounds are the relatively lower target affini-
ties and the metabolic instability of these compounds that may 
be extremely sensitive to protease degradation. Improving 
metabolic stability and pharmacokinetics can be attempted by 
modifying peptide sequences using specific coded or uncoded 
amino acids or amino acids with D  configurations. Cycling of 
the N-terminal with the C-terminal or with a side-chain, or the 
C-terminal with a side-chain and the side-chain with another 
side-chain, can also be utilized for such purpose. Another 
advantage is the possibility of designing analogs that can act 
as antagonists. Cell surface receptor antagonists show the dual 
advantage of not activating the biological pathways following 
receptor binding and have also been shown to have higher 
binding capacities to their agonist counterparts.42,43 These 
attractive physical properties coupled with their smaller size 
make peptides very appealing candidates for developing new 
target-specific nanoparticles.
Most peptide based targeting ligands are derived from 
known endogenous proteins capable of binding the target 
receptor with high affinity. Molecular modeling of new 
peptide sequences based on the known three-dimensional 
structure of the target receptor is also a possible strategy 
for rational design of new compounds, although such an 
approach requires thorough knowledge of the structure of 
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ligand/ receptor interaction.44 A further possibility for identify-
ing new peptide sequences for recognizing tumor- associated 
proteins is the use of phage display techniques.45
Once the binding sequence is identified a number of syn-
thetic strategies have been put in place in order to modify the 
surface of micelles, liposomes, or nanoparticles in order to 
display the targeting peptide sequence. One main  concern in 
this part of development is to achieve high coupling efficiency 
while distancing the bioactive peptide from the nanostruc-
ture surface in order to maintain the specific conformation 
required for high affinity binding to the target. The bioactive 
peptide may be introduced on the aggregate surface directly 
during nanostructure preparation by coupling the peptide 
to an amphiphilic moiety (pre-functionalization strategy; 
Figure 1A), or introducing the peptide on the surface of 
the nanostructures after they have been obtained (post-
functionalization; Figure 1B).
The first method, usually employed for the obtainment 
of peptide containing micelles and liposomes, needs a 
well-purified amphiphilic peptide molecule; it is mixed 
in appropriate solvents and in the chosen ratio with other 
amphiphilic molecules and phospholipids; then micelles or 
liposomes are obtained by evaporating the solvent or using 
extrusion procedures. The advantage of this approach is 
that one obtains a well-defined amount of bioactive mole-
cules in the aggregates and there are no impurities. With 
phospholipid
peptide sequence
A
=
=
+
biotin-peptide
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2)
A
A
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b)aliphatic - PEG-
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liposome
Peptide sequences:
CCK8: DYMGWMDF-NH2
QWAVGHLM-NH2
QLYENKPRRPYIL-NH2
pyroEHWSTGLRPG-NH2
fCFwKTCT-OH
[7–14]BN:
Octreotide:
Lutein:
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A
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Figure 1 Introduction of bioactive peptides on aggregate surfaces.
Notes: (A) The bioactive peptide may be introduced on the aggregate surface directly during nanostructure preparation by coupling the peptide to an amphiphilic moiety 
according to a pre-functionalization strategy; with this approach, however, the bioactive peptide is displayed on the external liposome surface as well as in the inner 
compartment. (B) Alternatively, peptide introduction can be performed after nanostructures have been obtained, according to a post-functionalization strategy. For the 
second approach, peptide coupling after liposome or nanoparticle preparation involves the introduction of suitable activated functional groups onto the external side of 
liposomes or nanoparticles for covalent or non-covalent peptide binding. To guarantee correct orientation of the targeting ligand, biorthogonal and site-specific surface 
reactions are necessary. Functional groups commonly used are: 1) amine for the amine-N-hydroxysuccinamide coupling method, 2) maleimide for Michael addition, 3) azide 
for Cu(I)-catalized Huisgen cycloaddition (CuAAC), 4) biotin for non-covalent interaction with avidin or triphosphines for Staudinger ligation, and hydroxylamine for oxime 
bond. In the inset are reported the peptide sequences.
Abbreviations: BN, bombesin; CCK8, cholecystokinin-8; NT, neurotensin; PeG, polyethylene glycol. 
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this approach, however, the bioactive peptide is displayed 
on the external liposome surface as well as in the inner 
compartment.
For the second approach, peptide coupling after lipo-
some or nanoparticle preparation involves the introduction 
of suitable activated functional groups onto the external side 
of liposomes or nanoparticles for covalent or non-covalent 
peptide binding. To guarantee correct orientation of the 
targeting ligand, biorthogonal and site-specific surface reac-
tions are necessary. The synthetic strategy should be aimed at 
optimizing reproducibility and yield of the coupling  reaction. 
Functional groups commonly used are: a) amine for the amine-
N-Hydroxysuccinimide coupling method; b) maleimide for 
Michael addition; c) azide for Cu(I)-catalyzed Huisgen 
cycloaddition (CuAAC); and d) biotin for non-covalent inter-
action with avidin or triphosphines for Staudinger ligation, 
and recently, hydroxylamine for oxime bond.46
A considerable number of molecular targets for peptides 
are either exclusively expressed or overexpressed on both 
cancer vasculature and cancer cells. They can be classified 
into three wide categories: integrins; growth factor recep-
tors (GFRs); and G-protein coupled receptors (GPCRs). 
These receptors offer attractive targets for anticancer 
therapeutics as they are often implicated in tumor growth 
and progression. Many nanoparticles and liposomes have 
been labeled with peptides capable of interacting with these 
receptors and have been reported in the literature in the last 
decade.  Nanoparticles grafted with the RGD sequence able 
to bind integrin receptors have been widely evaluated for 
the treatment of different cancers, such as ovarian cancer, 
melanoma, and breast carcinoma.47–49 Peptides targeting 
growth factor receptors have been utilized to functionalize 
liposomes encapsulating chemo-therapeutics.50 Peptides have 
also been developed to target the extracellular matrix of the 
diseased tissues, and this is an important alternative strategy 
to target unhealthy tissues which can also be incorporated 
with nanomedicine.51,52
This review will focus on delivery systems containing 
peptides that recognize GPCRs. GPCRs constitute a mem-
brane protein family involved in the recognition and transduc-
tion of signals as diverse as light, Ca2+, and small molecule 
signaling, including peptides, nucleotides, and proteins. The 
general structural features, obtained by indirect studies as 
well as X-ray crystallography, indicate the presence of seven 
transmembrane helices connected by three intracellular and 
three extracellular loops. The N-terminal domain is directed 
into the extracellular space and C-terminal points to the intra-
cellular space. Ligand binding to receptor is a crucial event 
in initiating signals, and the study of how ligands interact 
with their receptors can reveal the molecular basis for both 
binding and receptor activation. The ligand binding site for 
peptides has been found in the N-terminal extradomain or on 
the portion of the extracellular loops adjacent to the extracel-
lular moiety of the transmembrane helices. Knowledge of 
the structural details of this interaction could be very useful 
for designing ligands for targeted delivery. Unfortunately, 
detailed structural characterization of the ligand-receptor 
complex for most systems is very difficult to obtain. However 
several approaches, such as biochemical affinity, photoaffin-
ity labeling,53 and site-directed mutagenesis54 have allowed us 
to determine which amino acid residues are involved in bind-
ing. The interest in developing agonist or antagonist peptides 
against these receptors is based on the biological role these 
receptor pathways have in specific cancer types.
Overexpression of small peptide receptors has been 
documented for a wide number of cancers.41 As many as 
105–106 receptor molecules per cell or receptor densities in 
the pmol ⋅ mg−1 protein range have been reported for a variety 
of systems, such as somatostatin receptors in neuroendocrine 
tumors, cholecystokinin (CCK) receptors in medullary 
thyroid cancer, bombesin receptors in prostate and breast 
carcinoma, and several others.
We will review delivery systems targeting a family of 
regulatory peptide receptors overexpressed in specific cancer 
types, focusing particularly on receptors for somatostatin 
(SST), cholecystokinin (CCK), gastrin-releasing peptides 
(GRP/Bombesin), lutein, and neurotensin.
Somatostatin based  
delivery systems
At least five subtypes of somatostatin receptors (SSTRs; 
SSTRs 1–5) have been discovered: they belong to a distinct 
group within the superfamily of G-protein-coupled  receptors. 
SST binds these receptors with high affinity, with the main 
physiologic purpose of inhibiting some functions of the 
target cell, for example blocking growth-hormone release in 
the hypothalamus. This endogenous peptide is preferentially 
produced in neurons and secretory cells in the central and 
peripheral nervous system and in the gastrointestinal tract.55 
The different receptor subtypes show 50% sequence homol-
ogy, which is particularly evident in the transmembrane 
regions. Aside from the expression in normal tissues, SSTRs 
have been found in many different types of tumors, mostly 
of neuroendocrine origin, such as gastroenteropancreatic 
tumors, neuroblastomas, medulloblastomas, breast can-
cers, meningiomas, paragangliomas, renal cell carcinomas, 
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lymphomas, hepatocellular carcinomas, and small cell lung 
cancers. In general, SSTR2 is the most common SSTR 
subtype found in human tumors, followed by SSTR1, with 
SSTR3, 4 and 5 being less common. The high frequency of 
SSTR expression in human tumors has been exploited for 
diagnostic and therapeutic applications.
The wild type SST tetradecapeptide has a limited thera-
peutic value due to its short biological half-life (,3 minutes).55 
This feature pressed scientists to develop peptide analogs with 
improved stability to enzymatic cleavage and therefore with 
prolonged circulation time. The most successful derivative is 
octreotide (OCT).56 This eight amino acid analog, developed 
by Sandoz (now Novartis) is able to induce endocytosis by 
binding to SSTR2 with high affinity (inhibitory concentra-
tion [IC]
50 
=2nM), and SSTR 3 (IC
50 
=376 nM) and SSTR 
5 (IC
50 
=299 nM) to lesser degrees. OCT has been a subject 
of extensive structural studies, including nuclear magnetic 
resonance (NMR),57 in order to design peptide conjugates as 
vehicles for contrast agents or drugs. OCT peptide binding 
to receptors is not affected when chemical modifications 
are introduced on its N-terminus. Radiolabeled OCT conju-
gates are commonly used in clinical tumor diagnosis58 and 
in clinical trials for peptide receptor radiotherapy (PRRT).59 
OCT has been further used to enhance the delivery of drugs 
to tumor cells by chemically conjugating it with anti-tumor 
drugs.60 These promising results prompted many research-
ers to develop OCT as a specific targeting moiety to deliver 
nanocarriers incorporating anti-tumor drugs into tumor cells 
via SSTRs endocytosis (Table 2).
Liposomes and micelles
One of the most relevant issues for chemotherapeutic drugs 
is poor solubility in water and/or in buffers, which limits the 
quantities of drug that can be administered.  Supramolecular 
aggregates can improve the biodistribution and pharmacoki-
netics of these drugs.8 Moreover, as previously reported, 
severe side effects of these drugs can be reduced by enhanc-
ing delivery to the target tissue.13 In the last few years, many 
different aggregates have been developed to carry chemo-
therapeutic drugs to SSTR2 expressing tumors by coupling 
to the OCT peptide.61
Octreotide labeled aggregates may be obtained following 
the two approaches presented above. One strategy was based 
on synthesizing the OCT on trityl resin in solid phase and 
coupling the other molecular building blocks step by step. The 
advantage of this approach is to supervise all synthetic steps 
protecting all reactive functions in order to avoid collateral 
products. The most relevant disadvantage is the difficulty in 
Table 2 Octreotide labeled supramolecular aggregates or nanoparticles
Peptide conjugation methods Formulation Drug or nanoparticles References
OCT versus NHS-PeG-b-PCL Micelle: OCT-PeG-b-PCL PTX-salinomycin 65
OCT versus p-nitrophenylcarbonyl- 
PeG(100) monostearate
NLC: OCT-polyethylene glycol(100) 
monostearate (PGMS)
HCPT 67
OCT versus p-nitrophenylcarbonyl- 
PeG(100) monostearate
NLC: OCT-polyethylene glycol(100)  
monostearate (PGMS)
HCPT 68
OCT-PeG3400-DSPe Liposome: DSPC OCT-PeG3400-DSPe  
(different ratio)
Irinotecan CPT 11 70
OCT versus BocNHPeG-NHS Micelle OCT(Phe)-PeG-SA (OPS)/ 
(OCC) (in different ratio)
DOX 73
OCT versus BocNHPeG-NHS Micelles (OCT(Phe)-PeG-DOCA)  
(DAHC) 1:5 (molar ratio)
DOX 74
OCT versus pNP-PeG-Pe Liposome PC:Chol:OCT-PeG-Pe  
5:1:0.5 (molar ratio)
DOX 75
OCT versus DSPe-PeG-NHS Liposome ePC/chol/ 
DSPe-PeG/DSPe-PeG-OCT  
(15.9:4.1:5.7:0.3, w/w)
DOX 76
OCT amphiphilc solid phase synthesis Liposome (C18)2(AdOO)5OCT/ 
Peg1500Lys(Pt-aminoetGly)-Lys(C18)2  
1:9 (molar ratio)
Pt(II), DOX 77
DSPe-PeG2000-OCT (not declared) Liposome 
ePC/Chol/DSPe-PeG-OCT/CA- 
4;25:1.28:6:2,w/w
CA-4 and DOX 78
TOC-Boc AuNPs AuNPs 80
Octreotide versus AuNPs (∼20 nm) AuNPs 81
Abbreviations: AuNP, gold nanoparticles; Boc, tert-Butyl carbamates; DOX, doxorubicin; HCPT, 10-hydroxycamptothecin; NHS, succinimidyl carboxymethyl ester; OCT, 
octreotide; PeG, polyethylene glycol; PTX, paclitaxel; TOC, Tyr3-octreotide.
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purifying these molecules that are poorly soluble and which 
need to be solubilized in organic solvents, as they would 
aggregate in water-based buffers. An alternative strategy con-
sists in assembling the amphiphilic molecule in solution. The 
hydrophobic moiety and the hydrophilic linker are coupled on 
the N-terminus of the OCT after peptide purification. In this 
case side reactions are of concern as OCT has two primary 
amino groups (the N-terminus and the side chain of Lys) 
and the coupling reaction may get mono- or di-substituted 
derivatives. To limit the undesired products, reactions must 
be conducted at a pH value below 10. In certain instances 
a test of α Lys-C digestion is necessary to further confirm 
the coupling site. Trypsin cleaves peptide chains mainly at 
the carboxyl side of lysine or arginine, except when either 
is followed by proline. If the conjugation occurs at the Lys 
residue, there would be no change in the mass spectrum 
after trypsinization; otherwise the modification occurring 
at the N-terminus would exhibit a reduced mass fragment. 
The OCT amphiphilic molecules can self-assemble, or 
generate micelles or liposomes by mixing with a surfactant. 
Hydrophobic drugs are preferentially loaded in the core of 
micelles,8 whereas water soluble drugs could be carried in 
the inner compartment of liposomes or in the hydrophilic 
shell of micelles.
Important issues in the development of OCT coupled 
aggregates are confirming that there is adequate exposure on 
the aggregate surface, and also confirming the ability of the 
OCT peptides in recognizing and binding the target receptor. 
In order to characterize these aggregates for their suitability for 
in vivo use as selective targeting tools, it is possible to study 
peptide properties on the aggregate surface through classical 
chemical physical methods. Morisco et al61 developed OCT 
containing aggregates for use as drug carriers and magnetic 
resonance imaging (MRI) contrast agents. The monomers, 
synthesized on solid phase, contain, in the same molecule, 
three different functions: the chelating agent (DTPAGlu or 
DOTA); OCT; and a hydrophobic moiety based on two C18 
hydrophobic chains. These monomers (OCA-DTPAGlu, OCA-
DOTA) self-assemble in water solution, giving stable micelles. 
Fluorescence studies indicate, for the two compounds as well 
as for their gadolinium complexes (OCA-DOTA[Gd] and 
OCA-DTPAGlu[Gd]), the complete exposure of OCT on the 
micelle surface. In fact, the tryptophan emission at 345–350 
nm suggests a hydrophilic environment for this residue. 
Circular dichroism measurements show the predominant 
presence of an antiparallel beta-sheet peptide conformation 
characterized by a beta-like turn. This conformation has been 
demonstrated to be suitable for receptor binding.
The same group has also studied62 mixed aggregates 
formulated by co-assembling: a first monomer containing 
the OCT peptide, an ethoxyl spacer bound to the peptide 
N-terminus, and the hydrophobic moiety; a second monomer 
containing the same hydrophobic chains bound through a 
lysine residue to different polyamino-polycarboxy ligands; 
and a chelating agent such as DTPAGlu, DTPA, or DOTA 
to allow coordination of metal ions. Structural character-
ization of the aggregates indicates a shape and size of the 
supramolecular aggregates suitable for in vivo use. For these 
aggregates, fluorescent emission of the tryptophan residue 
at 340 nm also suggests exposure of the peptide to the water 
environment, thus available to interact with the SSTR2.
Later work by the group of Helbok et al63 demonstrated 
the in vitro and in vivo selective aggregate binding of OCT 
coupled PEGylated liposomal nanoparticles radiolabeled 
with indium-111. The OCT derivative was synthesized 
by cross-linking of the S-acetyl-mercaptopropionic acid 
peptide with Mal-DSPE-PEG2000.  Liposomes were 
obtained by mixing the OCT derivative with adequate 
amounts of palmitoyl oleoyl-phosphatidylcholine (POPC), 
lyso-stearyl- phosphatidylglycerol (Lyso-PG), distearyl-
 phosphatidylcholine–polyethyleneglycol-2000 (DSPE-
PEG2000), and dimyristoyl phosphoethanolamine-DTPA 
(DMPE-DTPA) in a molar ratio of 0.1:11:7.5:0.9:2, 
 respectively. Targeting properties of the OCT labeled lipo-
somes were evaluated in vitro on rat pancreatic tumor cells 
(AR42J), demonstrating specific binding and IC
50
 values 
in the low nanomolar range. Unfortunately only moderate 
uptake was observed when in vivo experiments were per-
formed in animals; this may be explained by the limited and 
slow accessibility of target receptors on tumor cells by large 
constructs such as these, compared to small peptides that 
show much more rapid diffusion and binding to the receptors 
and cellular internalization.
Similar proof of concept was reported by Petersen et al.64 
Liposomes (DSPC/Chol/DSPE-PEG2000/DSPE-PEG2000-
TATE in a molar ratio 50:40:9:1,  respectively) with an 
encapsulated positron emitter 64Cu for positron emission 
tomography (PET) imaging were tested in vivo in a mouse 
model. [Tyr3]-octreotate (TATE), an OCT analog, function-
alized with maleimide, was covalently attached to the distal 
end of DSPE-PEG2000 via a thioether bond. Biodistribution 
and pharmacokinetic properties of TATE coupled liposomes 
were compared with peptide free liposomes and with the 
radiolabeled peptide alone.  64Cu-loaded PEGylated liposomes 
derivatized with the TATE peptide displayed significantly 
higher tumor-to-muscle (T/M) ratio (12.7±1.0) compared 
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to control-liposomes without TATE (8.9±0.9) and to 64Cu-
DOTA-TATE peptide (7.2±0.3). These results demonstrate 
the feasibility of utilizing somatostatin analogs for specific 
targeting of the above described aggregates to tumors over-
expressing somatostatin receptors.
Paclitaxel (PTX) is a mitotic inhibitor used to treat 
patients with lung, ovarian, breast, head and neck cancers, 
and advanced forms of Kaposi’s sarcoma. This drug is poorly 
soluble in water and thus is a suitable candidate for loading in 
micelles. Zhang et al studied a combination of PTX and sal-
inomycin (SAL), an experimental drug recently found to be 
very effective on breast cancer stem cells.65 Both drugs were 
loaded in polyethylene glycol-b-polycaprolactone (PEG-b-
PCL) polymeric micelles obtaining OCT-(PTX)-PEG-b-PCL 
(OCT-M-PTX) and salinomycin (SAL)-loaded PEG-b-PCL 
(M-SAL). OCT was coupled to NHS-PEG-b-PCL through 
the activated NHS group in dimethyl sulfoxide (DMSO) solu-
tion. The prepared micelles have a diameter of approximately 
25–30 nm, and the encapsulation efficiency of the drug was 
.90%. The presence of the OCT peptide favors uptake of 
micelles in SSTR overexpressing MCF-7 breast cancer cells. 
Moreover, free OCT can inhibit such interaction confirm-
ing that cellular uptake is indeed occurring by a receptor-
 mediated mechanism. The efficacy of combination therapy 
using OCT-M-PTX plus M-SAL was confirmed in vitro and 
in MCF-7 xenografts in mice: the combination treatment 
results in a stronger inhibitory effect on tumor survival by 
killing both non-stem cancer cells and cancer stem cells.
Another water insoluble chemotherapeutic in a broad 
spectrum of cancers, including leukemias and cancers of 
the liver, stomach, breast, and colon, is a natural derivative 
of camptothecin, the 10-hydroxycamptothecin (HCPT) in 
lactone form. One way to improve the solubility of HCPT is 
to change the lactone form to the carboxylate form by adding 
NaOH. However, this leads to less activity and more unwanted 
toxicity.66 At the same time, HCPT has a short half-life in 
vivo and poor biodistribution. Obviously, pharmacokinetics 
of this molecule is improved by using drug carriers. Su et al67 
formulated HCPT-loaded nanostructured lipid carriers (NLC) 
made from poly(ethylene glycol)-poly(γ-benzyl-L-glutamate) 
(PEG-PBLG). At this amphiphilic polymer the conjugate 
OCT labeled polyethylene glycol monostearate (OPMS) was 
added. The labeling procedure was carried out in a solution 
of p-nitrophenyl-PMS adding OCT and incubating at pH 9. 
The OCT binding on PMS was determined by bicinchoninic 
assay (BCA) protein assay kit. Nanoparticle size depends on 
the different molar ratio of their components. In a more recent 
study, the authors demonstrated that surface density of the 
targeting moiety was crucial to determine physicochemical 
properties, drug release, cellular uptake, and cytotoxicity.
Compared to pharmacokinetic studies, modified NLCs 
had a longer circulation than NLC due to PEGylation effect, 
and OPMS-modified NLCs had larger mean residence 
time than PGMS-modified NLCs, showing 58.5 ng/mL at 
24 hours of drugs versus 15.8 ng/mL. Furthermore, qualita-
tive observation of cellular uptake by florescence microscopy 
showed higher uptake of OCT-modified NLCs on tumor cells 
(SMMC-7721) overexpressing somatostatin receptors, in 
comparison to OCT-modified NLCs uptake on control cells 
after incubation at 37°C for 2 hours.68
Irinotecan (CPT-11), another analog of camptothecin, 
induces a growth inhibition of tumor cells in medullary 
thyroid carcinoma (MTC).69 This derivative is water soluble 
but its use is limited because of many side effects. Iwase and 
Maitani70 overcame these problems by loading this drug in 
OCT decorated liposomes. Liposomes were formulated by 
mixing DSPC lipids with OCT-PEG
3400
-DSPE amphiphilic 
molecules in different ratios. The association of modified 
OCT-targeted liposomes with TT cells was significantly 
higher than non-targeted PEGylated liposomes and was 
significantly inhibited by empty OCT-targeted liposomes but 
not by free OCT. The authors suggest that the affinity of free 
OCT and OCT-CL to SSTR are not the same.70 After 96 hours 
of exposure, cytotoxicity of OCT-targeted liposomal CPT-11 
(IC
50
: 1.05 µM) was higher than free CPT-11 (IC
50
: 3.76 µM) 
or PEGylated liposomal CPT-11 (IC
50
: 3.05 µM). Moreover, 
OCT-targeted liposomal CPT-11 led to significantly higher 
antitumor activity and prolonged survival time compared 
with non-targeted liposomal and free CPT-11.
The major efforts in target delivery mediated by soma-
tostatin analogs have been devoted to carry DOX on tumor 
cells. DOX is a hydrophilic drug and can be loaded in 
micelles or in liposome inner compartments. The approval 
of DOXIL in 1995 opened a route to new formulations in 
order to improve efficacy and tolerability of the drug as 
compared with the non-liposomal counterparts or passive 
targeting aggregates.
Hydrophobilized polysaccharides polymeric micelles 
are currently very attractive for researchers due to their 
well-known nontoxicity and excellent biocompatibility 
and biodegradability.71 In the last few years, Zou et al72 
studied N-octyl-O,N-carboxymethyl chitosan (OCC) 
and N- deoxycholic acid-O,N-hydroxyethylation chitosan 
(DAHC) micelles. OCC and DAHC micelles exhibited good 
loading capacities for DOX, with a drug loading content 
(DLC) in the 22%–30% range. The first attempt to graft them 
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Figure 2 In vivo imaging of tumor-bearing mice after administration of Cy-7 loaded 
DAHC micelles (A) and Cy-7 loaded OPD(20%)-DAHC micelles (B) at 1, 6, 12, 
and 24 hours.
Note: Reprinted from Biomaterials, 33(27), Huo M, Zou A, Yao C, et al, Somatostatin 
receptor-mediated tumor-targeting drug delivery using octreotide-PeG-deoxycholic 
acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan 
micelles, 6393–6407, Copyright (2012) with permission from elsevier.74
Abbreviations: DAHC, N-deoxycholic acid-O,N-hydroxyethylation chitosan; 
OPD, OCT(Phe)-PeG-DOCA; h, hours.
with OCT was carried out, conjugating the N-terminal moiety 
to the free carboxylic groups of OCT.72 The reaction had an 
extremely low (about 3%) yield, which is largely due to the 
high molecular weights of OCT and chitosan derivatives, the 
strong hydrogen bonds in the chitosan backbone, and poor 
solubility of chitosan derivatives in organic solvent. This 
result pushed toward alternative mixed aggregates, adding 
to DAHC a ligand-PEG-lipid conjugate able to guarantee 
same time long circulation time in blood and ligand targeting. 
Therefore the peptide N-terminal function was anchored in 
solution to a PEG fragment and this moiety was conjugated 
to an aliphatic chain obtaining the OCT(Phe)-PEG-SA (OPS) 
monomer or to deoxycholic acid obtaining the OCT(Phe)-
PEG-DOCA (OPD).73
Micelles formulated by adding OPS to the final formu-
lation were not significantly affected with respect to size or 
shape. Their diameter is less than 120 nm with spherical 
shape and zeta potential of 30 mV. Enhanced tumor-targeting 
capacity was observed in BALB/c nude mice bearing MCF-7 
cancer xenografts as compared with the self-assembling OCC 
micelles. Moreover, pharmacodynamic studies demonstrated 
that DOX-OCC-OCT presented a stronger inhibition of tumor 
growth (86.7% versus 33.3%) and lower systemic toxicity 
compared to free DOX and DOX-OCC micelles.
Insertion of OPD in aggregate formulations showed no 
significant effect on drug loading properties while slightly 
increasing particle size (230 nm average diameter versus 
200 nm) and partly shielded the positive charges on the 
surface of micelles.7 Accelerated release rate of DOX 
from micelles were also observed after OPD modification, 
the release profile also exhibited pH-sensitive properties. 
 Compared to DAHC-DOX micelles, OPD-DAHC-DOX 
micelles exhibited significantly stronger cytotoxicity to 
human breast cancer cells (MCF-7; SSTRs overexpression) 
but had almost the same effect on human embryonic lung 
fibroblasts (WI-38 cells; no SSTRs expression). The results 
of flow cytometry and confocal laser scanning microscopy 
 further revealed that OPD-DAHC-DOX micelles could 
be selectively taken into tumor cells by SSTRs-mediated 
 endocytosis. In vivo investigation on nude mice confirmed that 
OPD-DAHC micelles possessed much higher  tumor-targeting 
capacity than the DAHC control and exhibited enhanced 
anti-tumor efficacy and decreased systemic  toxicity. Figure 2 
shows images of micelles in the tumor-bearing mice at 1, 
6, 12, and 24 hours after administration of fluorescent dye, 
Cyanine 7, encapsulated into DAHC (Figure 2A) micelles 
and OPD (20%)-DAHC micelles (Figure 2B). During the live 
imaging test, most of the Cy7 accumulated in liver and tumor 
after intravenous administration of both micellar formulations. 
However, preferential accumulation of fluorescence was obvi-
ous in the tumor site compared to the liver or other normal 
tissues at 12 and 24 hours after injection. Moreover, the 
OPD-DAHC micelles showed higher tumor-targeting effi-
ciency, which led to higher accumulation of micelles in the 
tumors than DAHC micelles. These results provide decisive 
evidence that the designed OPD-DAHC micelles are suitable 
for tumor-specific drug delivery. This high tumor targetability 
of micelles might be due to a combination of an EPR effect 
and receptor-mediated uptake of micelles (Figure 2).
OCT-polyethylene glycol-phosphatidylethanolamine (OCT-
PEG-PE) was developed for the assembling of  liposomes; the 
effect of OCT modification on the enhancement of the delivery 
and targeting of DOX-loaded liposomes was investigated in 
vitro and in vivo.75 OCT-PEG-PE was synthesized by a three-
step reaction. DOX loading was carried out by the well assessed 
ammonium sulfate gradient method. Both drug uptake assays 
and cell apoptosis assays suggested that octreotide-labeled lipo-
some (DOX-OL) noticeably increased the uptake of DOX by 
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fluorescent measurement (about 100% higher than that in unla-
beled liposome [DOX-CL] cases) in SMMC-7721 cells and 
showed a more significant  cytotoxicity compared to DOX-CL. 
The effect of DOX-OL was remarkably inhibited by free OCT. 
In contrast, no significant difference in drug cytotoxicity was 
found between DOX-OL and DOX-CL in CHO cells without 
obvious expression of SSTRs. The study of ex vivo fluorescence 
tissues imaging of BALB/c mice and in vivo tissue distribution 
of B16 tumor-bearing mice indicated that DOX-OL caused 
remarkable accumulation of DOX in melanoma tumors and the 
pancreas, in which the SSTRs are highly expressed. In another 
study,76 DOX-loaded OCT-DSPE-PEG monomer containing 
sterically stabilized liposomes (SSL) increased intracellular 
delivery of DOX in SSTR2-positive cells, through a mechanism 
of receptor-mediated endocytosis, as demonstrated by fluores-
cence spectrophotometry, confocal laser scanning microscopy, 
and flow cytometry studies. Confocal microscopy studies were 
carried out on NCI-H446, MCF-7, and Chinese hamster ovary 
(CHO) cells. After 3 hours of incubation with SSL-DOX, OCT-
SSL-DOX, or free DOX at DOX concentration of 10 µM at 
37°C, NCI-H446 and MCF-7 displayed more red fluorescence 
of DOX than SSL-DOX ones. In terms of CHO, there was no 
red fluorescence in both passive and active targeting liposome 
groups, proving no expression of SSTR2 on the cells. The active 
targeting was confirmed by treating with excess free OCT (5 
mg/mL). In this case, the uptake of OCT-SSL-DOX by NCI-
H446 cells at 37°C was significantly inhibited because of the 
preoccupation of receptors.
Compared to SSL, OCT modification on SSL exhibited 
little effect on the physicochemical properties of SSL. 
However, it reduced the circulation time of loaded-DOX to 
some extent in rats, increased cytotoxicity in SSTR2-positive 
tumor cells, enhanced drug accumulation in tumor tissue, 
and improved anticancer efficacy in SSTR2-overexpressing 
tumor model. The antitumor effect in vivo of OCT-SSL-DOX 
was demonstrated inhibiting tumor growth better than that 
of SSL-DOX (P,0.05).
Cis platinum is frequently used in combination with other 
drugs such as PTX, bleomycin, vinblastine, and in several 
trials with DOX.
As proof of concept of combined therapy based on DOX 
and platinum complexes, OCT grafted liposomal aggregates 
were recently formulated and studied.77 Mixed aggregates were 
formulated by co-assembling, at a 10:90 molar ratio, a first 
monomer containing two C18 hydrophobic moieties bound to 
the N-terminus of the cyclic OCT peptide, and spaced from 
the bioactive peptide by five units of dioxoethylene linkers, 
(C18)
2
(AdOO)
5
-OCT, and a second amphiphilic monomer 
containing a platinum complex anchored to the lipophilic 
tail, (C18)
2
PKAG-Pt. Mixed aggregates (C18)
2
-PKAG-Pt/
(C18)
2
(AdOO)
5
-OCT give large liposomes with a  diameter 
of 168 nm. DOX encapsulation in the inner compartment 
was obtained by using the pH gradient method.
Another example of combined therapy was the use, at the 
same time, of DOX and combretastatin. Combretastatin A-4, 
the principal cancer cell growth-inhibitory constituent of the 
Zulu medicinal plant Combretum caffrum, has been undergo-
ing preclinical development.78 However, the very limited water 
solubility of this phenol has complicated drug formation. 
Loading in aggregates could be an important improvement 
for its use. Both combretastatin A-4 (CA-4) and DOX were 
loaded in OCT-modified stealth liposomes in order to achieve 
the active delivery of these two drugs, followed by sequentially 
suppressing tumor vasculature and tumor cells. The drug 
loading efficiency of DOX was consistently greater than 95%, 
while it was 70%–80% for CA-4. The drug encapsulation effi-
ciency in liposomes was not affected by OCT modification. A 
rapid release of CA-4 followed by a slow release of DOX was 
observed in vitro. In fact, the release of CA-4 was more than 
60% at 8 hours, while DOX released less than 20% at 48 hours. 
The active targeted liposomes OCT-L[CD] showed a specific 
cellular uptake through ligand-receptor interaction and a higher 
antitumor effect in vitro against SSTR positive cell line. The 
in vivo sequential killing effect of such systems was found 
as evidenced by the fast inhibition of blood vessels and slow 
apoptosis-inducing of tumor cells. The anticancer efficacy of 
different formulations is displayed in Figure 3. As seen in Fig-
ure 3A, the tumor volume was always the smallest at each test 
point in OCT-L[CD] group, suggesting its stronger inhibition 
effect on solid tumor compared to other groups (P,0.05). The 
excised tumors in OCT-L[CD] group were also the smallest at 
the end of the test (Figure 3B). The results were in accordance 
with the antitumor study and cell uptake in vitro.
Metal nanoparticles
Metal nanoparticles have been extensively studied and offer 
extraordinary features for diagnostic as well as therapeutic 
applications.79 Multifunctional systems of gold nanoparti-
cles (AuNPs) capped by the [Tyr3]Octreotide (TOC) peptide 
were prepared and characterized by transmission electron 
microscopy (TEM) and UV-Vis (ultraviolet- visible), 
 infrared, and fluorescence spectroscopy.80 AuNPs and 
AuNP-TOC fluorescence emission spectra were obtained 
both in solution and in murine AR42J-tumor tissues. Results 
suggest that AuNP were functionalized with TOC through 
interactions with the N-terminal amine function of the 
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Figure 3 Antitumor efficiency of different treatments in MCF-7-bearing subcutaneous tumor models in nude mice. (A) Tumor volumes versus time. Data represent mean ± 
standard deviation (n=6). (B) Tumors excised at the end of the tests.
Note: Springer and Pharm Res, 29, 2012, 2902–2911, Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth 
liposomes, Dai w, Jin w, Zhang J, et al, Figure 10.78 with kind permission from Springer Science and Business Media.
Abbreviations: PBS, phosphate buffer solution; OCT, octreotide.
phenylalanine, the amide groups, and possibly with the 
indole group of the tryptophan residue. The fluorescence 
analyses in tissue revealed a recognition of the AuNP-TOC 
conjugate for the neuroendocrine tumor because of the 
lower energy position of the fluorescence resonance (692 
nm) with respect to that of the AuNP in the same tumoral 
tissue (684 nm). The emission band observed in the near 
infrared region (692 nm) opens, for AuNP-TOC, a potential 
use as theranostics.
The effect of laser heating, a well-characterized AuNP-
OCT system on HeLa cell viability, was evaluated as a suitable 
agent for plasmonic photothermal therapy in the treatment 
of cervical cancer.81 The peptide was conjugated to AuNPs 
(∼20 nm) by spontaneous reaction of thiol groups. HeLa cells 
were incubated at 37°C with AuNP-citrate, with AuNP-OCT, 
or without nanoparticles. After laser irradiation, the presence 
of AuNP caused a significant increase in the temperature 
of the medium (48°C versus 38.3°C without AuNP). The 
AuNP-OCT system resulted in a significant decrease in cell 
viability of up to 6% compared to the AuNP-citrate system 
(15.8%±2.1%). Two possible mechanisms could be at play: 
1) OCT alone exerts an effect on survival HeLa cells, or 2) the 
release of heat (∼727°C per nanoparticle) in the membranes 
or cytoplasm of the cells caused by the interaction between 
AuNP-OCT and somatostatin receptors reduced viability.
Cholecystokinin based  
delivery systems
The gastrointestinal peptides gastrin and cholecystokinin 
(CCK) exist in different molecular forms of variable length 
with the same five terminal amino acid sequences at their 
carboxyl termini. They act as neurotransmitters in the brain 
and as regulators of various functions of the  gastrointestinal 
tract, primarily at the level of the stomach, pancreas, and 
gallbladder.82 CCK and gastrin actions are mediated by sev-
eral receptor subtypes, the best characterized being CCK1 
and CCK2 receptors.83 The overexpression of either or both 
subtypes of these receptors has been found in certain human 
tumors and particularly in tumors of neuroendocrine origin. 
In particular, CCK2-R is overexpressed in a large percent-
age (90%) of medullary thyroid cancers, and to a lesser level 
in small cell lung cancers and in gastroenteropancreatic 
(GEP) tumors. Development of CCK2-R targeting radiop-
harmaceuticals for imaging and for radionuclide therapy has 
gained great interest. A wide number of CCK and gastrin 
derivatives displaying high affinity for the CCK2-R have 
been characterized over the past years for the purpose of in 
vivo receptor targeting for imaging and for therapy.84 In all 
derivatives, the chelating agents able to coordinate radioac-
tive metals are bound on the peptide N-terminus. In fact, 
modifications on peptide N-terminus do not affect receptor 
binding that is essentially due to the interaction of recep-
tor N-terminal extradomain with C-terminal fragment of 
the peptide ligand, as demonstrated by NMR studies85 and 
theoretical calculations.86
On the basis of these data, Accardo et al, in the last 
10 years, developed a wide class of CCK8 decorated 
 supramolecular aggregates (Naposomes) in order to  delivery 
contrast agents and drugs, thus acting like theranostics 
(Table 3).87 Naposomes are formulated by amphiphilic 
molecules containing a hydrophobic moiety with two C18 
aliphatic chains able to stabilize the aggregates in water 
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solution. The hydrophilic shell contains a chelating agent 
such as DOTA or DTPA or their metal complexes, and the 
CCK8 bioactive peptide. The chelating agent plays a double 
task: i) it gives the aggregation driving force for the presence 
of negative charges; and ii) it acts as polydentate ligand by 
complexing with high stability paramagnetic (Gd[III]) or 
radioactive (111In[III], 67Ga[III], 68Ga[III], 99mTc[V], 177Lu[III], 
or 64Cu[II]) metal ions for imaging application by MRI, 
PET, and  scintigraphy. Naposomes can be obtained by self-
assembling amphiphilic monomers containing in the same 
molecule: i) the hydrophobic moiety with two C18 aliphatic 
chains; ii) the chelating agent or its metal complexes; iii) the 
bioactive CCK8 peptide; and iv) PEG spacers of appropri-
ate length to allow the exposure of the bioactive moiety on 
the external surface of the resulting aggregate.88 The shape 
and the size of the resulting Naposomes can be modulated 
by adding commercial phospholipids, such as DOPC, to the 
synthetic amphiphilic monomer.
Another class of Naposomes can be formulated by 
 combining together two amphiphilic monomers (Figure 4). 
The first monomer contains the CCK8 peptide, a PEG spacer 
and two C18 hydrocarbon chains, while the second monomer 
contains the DOTA or DTPA chelating agent and the same 
hydrophobic moiety (general formula (C18)
2
LCCK8 and 
(C18)
2
CA, respectively). The morphology and size of the 
resulting aggregates (micelles, liposomes, or open bilay-
ers) are influenced by several parameters, such as pH, ionic 
strength, monomer structure (length of polioxiethylene 
 spacers), and composition and formulation procedure (dis-
solution in buffered solution or well-assessed procedures 
based on sonication and extrusion).87
All aggregates are able to act as theranostics, carrying 
contrast agents like Gd ions for MRI imaging, radioactive 
metals for nuclear medicine techniques, and chemother-
apy drugs.
Theranostic effects were demonstrated as proof of 
concept for the aggregate based on (C18)
2
DTPAGlu and 
(C18)
2
PEG
2000
CCK8 monomers in 70:30 ratio.89 The uptake 
of 111In-radiolabeled aggregates by A431 cells overexpress-
ing CCK2-R via transfection was demonstrated by in vitro 
experiments at 4°C and at 37°C. In vivo biodistribution 
showed that the overall retention of radiolabeled aggre-
gates in mice at 18 hours is very high, with essentially 
no  excretion of radioactivity over the observation period. 
Moreover, the radioactivity retention of the receptor-
positive xenografts was always higher than in their respec-
tive controls (Figure 4). Finally, cytotoxicity assays were 
performed by incubating the cells with peptide-containing 
aggregates filled with DOX in ratio 2:1 per aggregate. The 
overexpressing receptor cells survive significantly less than 
the control cells.
DOX has been also encapsulated in micelles obtained 
by self-assembling of (C18)
2
(AdOO)
5
CCK8 monomers.90 
These nanostructures, fully characterized by structural 
measurements, are able to encapsulate poorly water soluble 
molecules, such as pyrene, and DOX drug in their hydro-
phobic compartment. The encapsulation process, followed 
and quantified by fluorescence techniques, shows a strong 
preference of DOX for the inner hydrophobic environment 
of these nanostructures.
Further aggregates were formulated by adding the 
same (C18)
2
(AdOO)
5
CCK8 monomer to (C18)
2
DOTA in a 
10:90 molar ratio.91 (C18)
2
DOTA monomer that is respon-
sible for aggregate shape and size allows the obtainment of 
stable liposomes in water solution. DOX loading content is 
above 95% of the total drug added with a drug/lipid weight 
Table 3 Others receptor binding peptide coupled supramolecular aggregates
Receptor Peptide sequence Peptide conjugation Aggregates and lipid composition Drug References
CCK1–CCK2 CCK8 
DYMGwMDF-NH2
CCK8 amphiphilic solid phase  
synthesis
Micelle: (C18)2(AdOO)5CCK8 DOX 90
CCK1–CCK2 CCK8 
DYMGwMDF-NH2
CCK8 amphiphilic solid phase  
synthesis
Liposome: (C18)2DOTA, (C18)2 
(AdOO)5CCK8 9:1 molar ratio
DOX 91
CCK1–CCK2 CCK8 
DYMGwMDF-NH2
CCK8 amphiphilic solid phase  
synthesis
Bilayer-liposome: (C18)2DTPAGlu/ 
(C18)2PeG2000CCK8 in ratio 7:3
DOX 111In 89
LHRH Gonadorelin  
Pyr-HwSTGLRPGNH2
Gonadorelin-SH- Mal-Peg- 
DSPe
Liposome: HSPC/Chol/mPeG-DSPe/ 
Gon-PeG-DSPe 90:10:0.4 0.1%
MTX 107
LHRH Gonadorelin  
Pyr-HwSTGLRPGNH2
Gonadorelin-SH- Mal-Peg- 
DSPe
Liposome: HSPC/Chol/mPeG-DSPe/ 
Gon-PeG-DSPe 90:10:0.4 0.1%
MTX 108
Neurotensin RRPYIL Nt[8–13] Solid phase synthesis Liposome: DOPC-NT4Lys(C18)2 97:3 DOX 111
Neurotensin RRPYIL Nt[8–13],  
QLYeNKPRRPYIL Nt[1–13]
Solid phase synthesis Liposome: DOPC (NT8–13)L-(C18)2  
and DOPC (NT1-13)L-(C18)2
DOX 112
Abbreviations: AdOO, 8-amino-3,6-dioxaoctanoic acid; CCK, cholecystokinin; DOPC, 1,2-Dioleoyl-sn-glycero-3-phosphocholine; DOX, doxorubicin; DSPe, 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine; LHRH, luteinizing hormone releasing hormone; MTX, methotrexate; PeG, polyethylene glycol.
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Figure 4 Scheme of Naposomes formulation and their in vitro and in vivo behavior. Flow cytometric analysis of association of liposomal DOX and free DOX with human cells.
Notes: A431 cells (A) and HUveC cells (B) at a density of 1.3 ⋅ 106 cells/mL were incubated with CCK8/DOTA-DOX, DOTA-DOX, and free DOX at a final concentration 
of 1 µg DOX/mL for 1 hour at 48°C. Untreated cells served as negative control while free doxorubicin solution was used as positive control. The untreated cells 
(negative controls) and cells incubated with non-specific DOTA-DOX give identical behavior with overlapping curves. (C and D) Cytotoxicity of liposomal DOX against 
human cells on 431 cells and HUveC, respectively. Cells were incubated with CCK8/DOTA-DOX and DOTA-DOX at different concentration ranging between 0 and 
1,000 ng/mL at 37°C. After 8 hours, the medium was removed and after an additional 72 hours, an MTT assay was performed. Data are expressed as percent of negative 
control. (E) γ-camera image (dorsal view) obtained prior to dissection of one of the animals 18 h after injection of radiolabeled aggregates clearly shows higher concentration 
of the radiolabel in the receptor positive xenograft (+, left flank) compared with the control tumor (−, right flank). (A–D) Reproduced with permission from John wiley 
and Sons. Morisco A, Accardo A, Tesauro D, Palumbo R, Benedetti e, Morelli G. Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery 
to tumor cells. Biopolymers. 2011;96:88–96.91 Copyright © 2011 wiley Periodicals, Inc. (E) Reproduced with permission from John wiley and Sons. Accardo A, Tesauro D, 
Aloj L, et al. Peptide-containing aggregates as selective nanocarriers for therapeutics. ChemMedChem. 2008;3(4):594–602.89 Copyright © 2008 wILeY-vCH verlag GmbH & 
Co. KGaA, weinheim.
Abbreviations: CCK, cholecystokinin; DOTA, 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid; DOX, doxorubicin; HUveC, human umbilical vein endothelial 
cell; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide.
(w)/w ratio of 0.134. The cellular uptake of the peptide 
containing targeted liposomal DOX on A431 and HUVEC 
cells was 70- and 8-fold higher than that for non-targeted 
liposomes, respectively, indicating that the bioactive CCK8 
peptide is able to enhance uptake into the A431 carcinoma 
cells and, at lower amounts, in the endothelial HUVEC cells 
(Figure 4).
Bombesin based delivery systems
Four receptor-subtypes associated with the Bombesin 
like peptides (BLP) family have been identified: sub-
type 1 (termed GRP-R or BB2); subtype 2 (termed NMB-R 
or BB1);  subtype 3 (termed BRS-3) classified as an orphan 
receptor because its natural ligand is yet to be identified; and 
subtype 4 (termed BB4). In addition to their physiological 
functions, these  receptors have been found overexpressed in 
prostate, breast, small cell lung,92 ovarian, and gastrointestinal 
stromal tumors.93
Peptides able to bind these receptors belong to a family 
of brain-gut peptides. BN (bombesin) is a 14-amino-acid 
peptide present in amphibian tissues, whereas GRP, its human 
counterpart, consists of 27 amino acids. GRP and BN differ 
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by only one of the ten C-terminal residues playing similar 
biological activities.94 GRP acts primarily in the central and 
enteric nervous systems where it regulates several physiologi-
cal processes including satiety, thermoregulation, circadian 
rhythm, smooth muscle contraction, immune function, as 
well as the release of other peptide hormones.
The fourteen BN residues, its eight-residues C-terminal 
peptide sequence ([7–14]BN), and many other BN analogs 
acting as agonist or antagonists, have been modified to 
selectively carry diagnostic or therapeutic agents to their 
receptors. Many studies demonstrate that the [7–14]BN 
fragment conjugated on the N-terminus with amino acid 
linkers, aliphatic or hydrophilic moiety preserves the affin-
ity for receptors.95,96 Moreover, the pan-bombesin analog 
[β-Ala11, Phe13, Nle14] BN[7–14] conjugated through a 
linker to dextran covalently cross-linked to iron oxide (CLIO) 
is able to bind to PC-3 cells overexpressing GPR receptors, 
as indicated by MRI studies.97
Liposomes and micelles
On the basis of MRI results, Accardo et al developed 
new bombesin based supramolecular aggregates acting as 
 theranostic agents (Table 4).98 They were obtained by the 
combination of two amphiphilic synthetic monomers: a first, 
more abundant, monomer based on a lysine residue carrying 
a DOTA chelating agent on the epsilon amino function and 
an hydrophobic moiety with two C18 chains on the alpha 
amino function; and a second monomer containing the same 
hydrophobic moiety, PEG spacers, and the 7–14 BN peptide 
 fragment. The DOTA containing monomer drives to form 
stable liposomes in water solution independently from the 
presence of 10% in peptide monomer, as demonstrated by 
SANS (small angle neutron scattering) and DLS (dynamic 
light scattering) techniques. The liposome hydrodynamic 
radius and bilayer thickness were found to be around 200 nm 
and 4 nm, respectively. This structure is different from that 
observed for similar aggregates, in which the presence of 
DTPAGlu chelating agent in the most abundant amphiphilic 
monomer produces highly polydisperse aggregates (rod-like 
micelles, open bilayers, and vesicles). This behavior could be 
explained on the basis of the lower negative charge (−3) of 
DOTA versus DTPAGlu (−5); a decrease of the electrostatic 
repulsion between the headgroups favors the formation 
of large and low curvature aggregates, such as liposomes. 
Different systems were studied depending on the length 
of the PEG spacer in the peptide containing monomer. 
In vitro data of radioactive labeled 111In-(C18)
2
DOTA/
(C18)
2
AdOO
5
-[7–14]BN liposomes show specific binding 
to receptor expressing cells, while the presence of a longer 
PEG (Peg3000) on the external liposomal surface hides the 
bioactive peptide, preventing receptor binding. In vivo experi-
ments display the expected biological behavior of aggregates 
of such size and molecular composition, and preliminarily 
confirm the aggregates’ ability to specifically target receptor 
expressing xenografts. At later stages, liposomes based on co-
aggregation of 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC) phospholipid with the amphiphilic synthetic mono-
mer MonY-BN were developed.99 This monomer contains, 
in a single molecule, the [7–14]BN peptide fragment, the 
DTPA chelating agent, the hydrophobic moiety with two 
C18 alkyl chains, and a PEG spacer of 1500 Daltons. DOX 
loading capability of DSPC/MonY-BN (97:3 molar ratio) 
liposomes is 0.20 (drug/lipid, w/w), higher than that found for 
the approved liposomal drug DOXIL (0.125). The selective 
liposome binding was evaluated in vitro by gamma count-
ing experiments after radiolabeling of liposomes with 111In 
isotopes.  Cytotoxic assays showed significantly lower cell 
survival after cell incubation with DSPC/MonY-BN/DOX 
liposomes, compared to DSPC/DOX treated cells. Intrave-
nous treatment of PC-3 xenograft-bearing mice produced 
Table 4 Bombesin analogs labeled supramolecular aggregates or nanoparticles
Peptide sequence Peptide conjugation Aggregates and lipid composition Drug References
[7–14] BN 
QwAvGHML-NH2
BN amphiphilic solid phase  
synthesis
Liposome: (C18)2DOTA/ 
(C18)2(AdOO)5BN and (C18)2DOTA/ 
(C18)2Peg3000BN (9:1 molar ratio)
DOX 98
[7–14] BN 
QwAvGHML-NH2
BN amphiphilic solid phase  
synthesis
Liposome: DSPC/MonY-BN  
(1:0.03 molar ratio)
DOX 99
AhoH-DPheQwAvNMeGHSta- 
L-NH2
BN analog amphiphilic solid  
phase synthesis
Liposome: DSPC/MonY-BN-AA1  
(1:0.03 molar ratio)
DOX 101
Ac-Cys-Ahx-QwAvGHLMNH2 Ac-Cys-Ahx-BN 
NH2-AuNP
AuNPs 104
7–14 BN 
QwAvGHML-NH2
7–14 BN functionalized on  
N-terminus with lipoic acid AuNPs
AuNPs 103
Abbreviations: AdOO, 8-amino-3,6-dioxaoctanoic acid; AhOH, 21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid; AuNP, gold nanoparticles; Ahx, aminohexanoic acid; 
BN, bombesin; DOX, doxorubicin; DSPC, 1,2-Distearoyl-sn-glycero-3-phosphocholine.
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higher tumor growth inhibition (60%) compared with non-
specific liposomes (36%) relative to control animals.
The relatively short in vivo circulation time of this natural 
peptide fragment suggested to many researchers that modi-
fying peptide sequences can enhance protease stability.100 
A very recent attempt was carried out, replacing the Leu13-Met14 
C-terminal sequence with Sta13-Leu14, for stabilization against 
aminopeptidase, and inserting N-methyl-glycine in place of 
natural glycine in order to reinforce the Val-Gly bond that 
could be sensitive to carnitine enzyme.100 Moreover, Mansi 
et al100 demonstrated that replacement of Leu13 with the Sta13 
residue provides antagonist properties to the peptide. Finally, 
the presence of D-Phe residue on the N-terminal end of the 
BN bioactive sequence increases binding and stability. DSPC/
MonY-BN-AA1/DOX liposomes containing the modified 
BN-AA1 bombesin sequence were able to target PC-3 cells 
in a selective way and provide therapeutic efficacy in PC-3 
cells and PC-3 xenograft bearing mice to a slightly greater 
extent than DSPC/MonY-BN/DOX liposomes.101
Metal nanoparticles
Several metal nanoparticles were labeled to target BN recep-
tors for tumor therapy and treatment monitoring.102 AuNPs 
have been used in photothermal therapy for the destruction 
or molecular surgery of cancer cells or tumors. When irradi-
ated with a focused laser in the near-infrared region (NIR) of 
suitable wavelength, targeted aggregates of AuNPs can kill 
cancer cells. At the same time, they are carriers of anticancer 
drugs or contrast agents, providing synergistic advantages in 
oncology as it relates to molecular imaging and therapy.
Chanda et al103 synthesized a library of GRP receptor 
nanoplatforms by conjugating AuNPs with BN peptides. The 
7–14 BN peptide was functionalized on N-terminus with lipoic 
acid, which contains a disulfide group able to bind AuNPs. 
Reactive sites on AuNPs surface allow the incorporation of 
varying amounts of BN peptides and  provide a library of 
AuNP-BN conjugates with different ratios. The hydrodynamic 
diameter of AuNP-BNs (115–155 nm) is compatible for effec-
tive penetration within tumor vasculature, which has porosity 
in the 150–300 nm range. In vitro cellular interactions and 
binding affinities (IC
50
) toward GRP receptors on human pros-
tate cancer cells and in vivo studies using AuNP-BN and its 
radiolabeled surrogate198 exhibited high binding affinity (IC
50
 
in microgram ranges), providing unambiguous evidences that 
AuNP-BN constructs are GRP-receptor-specific. Indeed, the 
nanoparticles were accumulated with high selectivity in GRP-
receptor-rich pancreatic acne in normal mice and in tumor cells 
of prostate-tumor-bearing, severe combined immunodeficient 
mice. More recently, Hosta-Rigau et al104 exploited the  ability 
of BN labeled AuNPs to vehicle an analog of the RAF peptide. 
This pharmaceutical active peptide ligand is able to inhibit 
Rb-Raf-1 binding in vivo and therefore inhibits tumor growth 
and angiogenesis.105 BN and RAF peptides were conjugated to 
nanoparticles by modifying gold surface with Cys residues and 
an aminohexanoic acid (Ahx) acting as spacer. Internalization 
mechanism of peptide-AuNP conjugates and enhancement of 
activity and selectivity of peptide multifunctionalized conju-
gates was observed by confocal laser scanning microscopy. 
Preliminary results confirm that conjugates in which BN is 
present penetrate GRPr overexpressing cells, as indicated by 
coloration of nanoconjugates of Ac-Cys-Ahx-BN and Ac-Cys-
Ahx-RAF inside cells due to the accumulation and reflection 
of the AuNP. The enhancement in activity and selectivity could 
contribute to a potential improvement of the efficacy of RAF 
for therapy by reducing the therapeutic index. Furthermore, 
this strategy provides an opportunity for the controlled deliv-
ery of AuNPs used as cargoes for a localized (nanometrically) 
therapy like the so-called molecular surgery.
Other systems
Lutein releasing hormone  
based delivery systems
Luteinizing hormone (LH)-releasing hormone (also referred 
to as GNRH or LHRH) is the central regulator of reproduc-
tion via its action upon the hypothalamic-pituitary axis. The 
LHRH receptors are characteristically overexpressed in 
many different tumors, such as breast, ovarian,  endometrial, 
and prostate cancers, but barely expressed in healthy vis-
ceral organs. The elevated expression of LHRH receptors 
in  various cancers makes it possible to use them as target 
moieties to deliver cytotoxic agents to these tumors.106 Some 
small peptide LHRH analogs were able to recognize a broad 
variety of tumors, but not normal cells. Targeting these small 
peptides has certain advantages, including ease of prepara-
tion, lower antigenicity, and increased stability over the use 
of conventional protein macromolecules.
Liposomes were prepared using a lipid molar ratio HSPC/
Chol/mPEG–DSPE 90:10:0.4, and 0.1% mol  Mal-PEG–DSPE 
was further inserted for ligand conjugation. Gonadorelin 
(Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH
2
) was first 
thiolated through incubation with Traut’s reagent. Thiolated 
gonadorelin was chemically coupled to N-[(3-maleimide-
1-oxopropyl) aminopropyl polyethylene glycol-carbamyl] 
distearoylphosphatidylethanolamine via a thioether bond 
and subsequently inserted into polyethylene glycol-grafted 
liposomes. Efficient transfer of gonadorelin-PEG-DSPE from 
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micelles into the outer monolayer of liposomes was achieved 
at a temperature above the phase transition of the lipids 
(around 60°C) to obtain the gonadorelin modified liposomes. 
MTX was encapsulated into the gonadorelin-modified or 
control nontarget liposome formulation using transmembrane 
ammonium sulfate gradient-driven loading procedures. The 
size of the liposomes was in the range of 120–150 nm. The 
size of the gonadorelin modified liposomes was found to 
be 15–20 nm larger than the original liposomes. The zeta 
potential was slightly lower after the ligand conjugation, 
due to the presence of peptides attached to the liposomal 
membrane via a longer PEG linker. Regardless of this, the 
encapsulation of MTX did not significantly affect the particle 
size of the liposome.107
The intracellular uptake experiments were carried out on 
MCF-7 cells with either gonadorelin modified MTX loaded 
liposomes (LHRH-MTX-SL) or non-target MTX loaded lipo-
somes (MTX-SL) at a dose of 0.2 mg of total lipids (10 µg/mL 
as MTX) per dish. After 4 hours incubation at 37°C, the internal-
ized liposomes were visualized using a confocal laser scanning 
microscope, resulting in an intense fluorescence in both the cyto-
plasm and at the cellular membrane. Meanwhile, for MTX-SL, 
the fluorescence intensity was much lower overall and mainly 
located at the cell surface respectively108 (Figure 5).
Neurotensin based delivery systems
Neurotensin (NT) is a 13 amino acid peptide isolated 
from calf hypothalamus; its amino acid sequence is 
QLYENKPRRPYIL, with the C-terminus displaying the 8–13 
(RRPYIL) active fragment. NT has the dual  function of 
 neurotransmitter or neuromodulator in the nervous system 
and local hormone in the periphery. NT receptor type 1 
(NTR1) is overexpressed in severe malignancies, such as 
small cell lung cancer and colon, pancreatic, and prostate 
carcinomas.17 NT has additional well-established targets on 
the cell surface: NT receptor 2; NT receptor 3 (NTR3, or 
sortilin); and SorLA (LR11) – these latter two membrane 
proteins belong to the novel Vps10p-domain family.109
NT shows a very short half-life in vivo; Falciani et al 
designed tetrabranched peptides (NT4) containing four copies of 
the active NT sequence and acting as tumor targeting agents.110 
It is well known that peptides synthesized in a branched arrange-
ment not only become resistant to proteases but also increase 
linear peptide biological activity through multivalent binding. 
Additionally, branched NT peptides have been proven to dis-
criminate between binding of tumor versus healthy tissue in 
human surgical samples, validating increasing interest.
Target liposomes were prepared by mixing together 
DOPC phospholipids and (C18)
2
Lys(NT8-13)
4
 monomer 
Figure 5 Liposomes encapsulating mitoxantrone uptake in various cell lines followed by confocal laser scanning fluorescence microscopy. Cell lines were treated with either 
LHRH-MTX-SL or MTX-SL for 4 hours at 37°C. (A) LHRH-MTX-SL in LHRH receptor high-expressing MCF-7 cells; (B) MTX-SL in LHRH receptor high-expressing MCF-7 
cells; (C) MCF-7 cells treated with drug-free medium used as a control; (D) LHRH-MTX-SL in LHRH receptor low-expressing SK-Ov-3 cells; (E) MTX-SL in LHRH receptor 
low-expressing SK-Ov-3 cells; (F) SKOv-3 cells treated with drug-free medium used as a control.
Note: Copyright © 2010. Reproduced with permission of Dove Medical Press. He Y, Zhang L, Song C. Luteinizing hormone-releasing hormone receptor-mediated delivery 
of mitoxantrone using LHRH analogs modi fied with PEGylated liposomes. Int J Nanomedicine. 2010;5:697–705.108
Abbreviations: LHRH, luteinizing hormone releasing hormone; MTX, methotrexate; SL, loaded liposomes.
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Figure 6 Confocal microscopy of (A) HT29 and (B) Te671 cells incubated with 
DOPC-(C18)2Lys(NT8-13)4-DOX liposomes (200 nm, right) and with DOPC-DOX 
liposomes (200 nm, left) for 2 hours at 37°C. Plasma membranes were stained with 
lectin-FITC (green).
Note: Reproduced with permission from Falciani C, Accardo A, Brunetti J, 
et al. Target-selective drug delivery through liposomes labeled with oligobranched 
neurotensin pep tides. ChemMedChem. 2011;6(4):678–685.111 Copyright © 2011 
wILeY-vCH verlag GmbH & Co. KGaA, weinheim.
Abbreviations: DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOX, doxo ru - 
bicin; FITC, fluorescein isothiocyanate.
obtained by using a solid phase synthesis.111 In vitro cytotoxic 
results of functionalized liposomes loaded with DOX show a 
clear advantage, in comparison to native liposomes, in tumor 
cell drug internalization, both in HT29 and TE671 cells. 
Fluorescent-activated cell sorting (FACS) analyses are in line 
with these results, showing a fluorescence signal increase in 
both cell lines when NT4 decorated liposomes are compared 
to the non-functionalized analogs (Figure 6). All of these 
effects can be attributed to a higher rate of internalization 
of the decorated liposomes.
Recently, the comparison of the branched (NT4) versus 
linear (NT) peptides demonstrated liposomes decorated with 
branched peptides present a better profile in drug delivery, 
with respect to liposomes decorated with the correspondent 
monomeric peptides.112
Conclusion and future perspectives
Beside new therapies and new drugs, the innovative adminis-
tration methods of well tested active principles can represent 
an additional weapon in the fight against cancer. Compared to 
conventional small molecule-based therapy, nano-therapeutic 
systems have several potential advantages: they can remain in 
the circulation for an extended period of time when injected 
intravenously, and present high payload capacity, reduced 
toxicity to healthy tissues, and improved antitumor efficacy. 
The active targeting by means of drug encapsulated nanopar-
ticles decorated with targeting bioactive moieties represents 
the next frontier in drug delivery: it reduces drug side effects 
and increases the therapeutic index. Peptides, based on their 
chemical and biological properties, could have a prevalent 
role in directing drug encapsulated nanoparticles, such as 
liposomes, micelles, or hard nanoparticles, toward tumor tis-
sues. Therapeutic agents based on nanovectors decorated with 
peptides targeting GPCRs membrane receptors overexpressed 
by cancer cells have been reviewed in this article. Despite the 
promising in vitro and in vivo results here described, all com-
pounds reported in literature are still in preclinical phases. For 
most of the described systems, it is possible to schedule Phase 
I clinical trials, which can definitively legitimize the use of 
peptide decorated nanoparticles as target selective delivery 
systems for cancer therapy. Moreover, many efforts should 
be made to search for other peptide sequences to decorate 
drug encapsulated nanovectors.
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